Improvement of Screening Accuracy of Mini-Mental State Examination for Mild Cognitive Impairment and Non-Alzheimer’s Disease Dementia by Supplementation of Verbal Fluency Performance

논문상세정보
' Improvement of Screening Accuracy of Mini-Mental State Examination for Mild Cognitive Impairment and Non-Alzheimer’s Disease Dementia by Supplementation of Verbal Fluency Performance' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • mild cognitive impairment
  • mini-mentalstateexamination
  • non-alzheimersdiseasedementia.
  • screeningaccuracy
  • verbal fluency
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
104 0

0.0%

' Improvement of Screening Accuracy of Mini-Mental State Examination for Mild Cognitive Impairment and Non-Alzheimer’s Disease Dementia by Supplementation of Verbal Fluency Performance' 의 참고문헌

  • Verbal fluency performance in amnestic MCI and older adults with cognitive complaints
    Nutter-Upham KE Arch Clin Neuropsychol 23 229-241 [2008]
  • Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
    Roman GC Neurology 43 250-260 [1993]
  • Understanding verbal fluency in healthy aging, Alzheimer’s disease, and Parkinson’s disease
    McDowd J Neuropsychology 25 210-225 [2011]
  • The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia
    Meulen EF J Neurol Neurosurg Psychiatry 75 700-705 [2004]
  • The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer’s disease: relationship to episodic and semantic memory impairment
    Perry RJ Neuropsychologia 38 252-271 [2000]
  • The mini-mental state examination: a comprehensive review
    Tombaugh TN J Am Geriatr Soc 40 922-935 [1992]
  • The concise cognitive test for dementia screening: reliability and effects of demographic variables as compared to the mini mental state examination
    Srinivasan S Neurol India 58 702-707 [2010]
  • The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
    Nasreddine ZS J Am Geriatr Soc 53 695-699 [2005]
  • The Montreal Cognitive Assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia
    Dong Y Int Psychogeriatr 24 1749-1755 [2012]
  • The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease
    Morris JC Neurology 39 1159-1165 [1989]
  • The Clinical Dementia Rating (CDR): current version and scoring rules
    Morris JC Neurology 43 2412-2414 [1993]
  • Subscores of the FAB differentiate frontotemporal lobar degeneration from AD
    Lipton AM Neurology 65 726-731 [2005]
  • Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset
    Saxton J Neurology 63 2341-2347 [2004]
  • Neuropsychological Assessment, 4th Edition
    Lezak MD - [2004]
  • Mini-mental state : A practical method for grading the cognitive state of patients for the clinician
    Folstein, M. F. J Psychiatr Res 12 189-198 [1975]
  • Mild cognitive impairment: beyond controversies, towards a consensus:report of the International Working Group on Mild Cognitive Impairment
    Winblad B J Intern Med 256 240-246 [2004]
  • Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease
    Geslani DM Dement Geriatr Cogn Disord 19 383-389 [2005]
  • Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice
    Wind AW Int J Geriatr Psychiatry 12 101-108 [1997]
  • Inhibitory functioning in Alzheimer’s disease
    Amieva H Brain 127 949-964 [2004]
  • Handbook of Cognitive Aging: Interdisciplinary Perspectives
    Kemper S 181- [2008]
  • Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria
    Neary D Neurology 51 1546-1554 [1998]
  • Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease
    Slachevsky A Arch Neurol 61 1104-1107 [2004]
  • EXIT, QED, and DSM-IV: very early Alzheimer’s disease
    Royall DR J Neuropsychiatry Clin Neurosci 6 62-65 [1994]
  • Do the ABCS 135 short cognitive screen and its subtests discriminate between normal cognition, mild cognitive impairment and dementia?
    Standish TI Int J Geriatr Psychiatry 22 189-194 [2007]
  • Differentiating Alzheimer’s disease from subcortical vascular dementia with the FAB test
    Oguro H J Neurol 253 1490-1494 [2006]
  • Diagnostic and Statistical Manual of Mental Disorders. fourth edition
  • Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
    McKeith IG Neurology 65 1863-1872 [2005]
  • Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries
    Lee JH J Gerontol B Psychol Sci Soc Sci 57 P47-P53 [2002]
  • Conversion from mild cognitive impairment to probable Alzheimer’s disease predicted by brain magnetic resonance spectroscopy
    Modrego PJ Am J Psychiatry 162 667-675 [2005]
  • Complex semantic processing in old age: does it stay or does it go?
    Mayr U Psychol Aging 15 29-43 [2000]
  • Comparing the clinical usefulness of the Institute of Cognitive Neurology (INECO) Frontal Screening (IFS) and the Frontal Assessment Battery (FAB) in frontotemporal dementia
    Gleichgerrcht E J Clin Exp Neuropsychol 33 997-1004 [2011]
  • Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease
    McKhann G Neurology 34 939-944 [1984]
  • Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment
    Lee JY JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY 21 104-110 [2008]
  • A method of comparing the areas under receiver operating characteristic curves derived from the same cases
    Hanley JA Radiology 148 839-843 [1983]
  • A 7 minute neurocognitive screening battery highly sensitive to Alzheimer’s disease
    Solomon PR Arch Neurol 55 349-355 [1998]